The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.

Inclusion Criteria:

• Diagnosis of dementia of the Alzheimer's type
• Males, and females who are surgically sterile or one year postmenopausal
• A primary caregiver willing to accept responsibility for supervising the treatment

Exclusion Criteria:

• Any condition (other than Alzheimer's) that could explain patient's dementia
• An advanced, severe or unstable disease that may put the patient at special risk
• Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease